Nikhil I. Khushalani, MD
Vice Chair and Senior Member, Cutaneous Oncology
Chief, Medical Oncology
Moffitt Cancer Center
- Discuss the elements of immune dysfunction that drive the tumorigenesis of cutaneous squamous cell carcinoma (cSCC)
- Review risk stratification of patients with cutaneous squamous cell carcinoma to determine who are at high risk of recurrence
- Describe the application of medical practice guidelines and supporting trial data to the treatment of patients with locally advanced and metastatic cSCC
This CME initiative is designed to meet the educational needs of dermatologists, surgical dermatologists, Mohs surgeons, and other healthcare practitioners who care for patients with advanced or metastatic cutaneous squamous cell carcinoma.
ACCREDITATION AND DESIGNATION STATEMENTS
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with cutaneous squamous cell carcinoma.
CNE Credits: 0.75 ANCC Contact Hours.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 0.75 contact hours of continuing nursing education of RNs and APNs.
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 0.75 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Nikhil I Khushalani, MD, discloses that he has received research funding (Institute) from BMS, Merck, Amgen, GSK, HUYA, Regeneron, Novartis, Celgene. He is on the Advisory Boards/has received honoraria from HUYA, BMS, EMD Serono, Genentech, Regeneron, Immunocore, Merck, Sanofi. He is on the Data Safety Monitoring Board for AstraZeneca and Incyte. Dr. Khushalani owns stock in TransEnterix, Bellicum, and Amarin Corporation.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Outcomes Coordinator for Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Melissa A Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
Amanda Jenkins, Associate Program Manager for Med Learning Group has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete and submit the evaluation form to Med Learning Group.
You will receive your certificate after the activity.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
RELEASE DATE: February 10, 2022
EXPIRATION DATE: February 10, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.